Evidence map›Paper›PMID 41372725›Full record

ArticleJapanese journal of ophthalmology2026

Use of brolucizumab in refractory neovascular age-related macular degeneration: characteristics and biomarkers of intraocular inflammation from an Asian real-world study.

Chun Pao Chang, Yih-Shiou Hwang, Hung-Da Chou, Ling Yeung, Eugene Yu-Chuan Kang, Wei-Chi Wu, Chi-Chun Lai, Laura Liu, Jheng-Siou Wu, Kuan-Jen Chen and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chun Pao ChangDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Yih-Shiou HwangDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Hung-Da ChouDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Ling YeungCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Eugene Yu-Chuan KangDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Wei-Chi WuDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Chi-Chun LaiCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Laura LiuDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Jheng-Siou WuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Kuan-Jen ChenDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
An-Ning ChaoDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Jui-Yen LinDepartment of Ophthalmology, Tucheng Hospital, New Taipei City, Taiwan.
Yen-Ting ChenDepartment of Ophthalmology, Tucheng Hospital, New Taipei City, Taiwan.
Tsung-Hsien TsaiDepartment of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.
Ming-Chih HoDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan.
Yi-Hsing ChenDepartment of Ophthalmology, Chang Gung Memorial Hospital, Linkou Main Branch, No. 5, Fuxing St., Taoyuan City, 333, Taiwan. yihsing@gmail.com.ORCID http://orcid.org/0000-0002-2682-939X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the clinical features and biomarkers associated with intraocular inflammation (IOI) following brolucizumab treatment in Asian switched neovascular age-related macular degeneration (nAMD) patients. STUDY

designMulti-center, retrospective cohort study.

methodsThis study included 109 eyes from 93 nAMD patients switched from other anti-vascular endothelial growth factor (VEGF) agents to brolucizumab (Beovu) without loading. Baseline characteristics, IOI timing, initial symptoms, and risk factors were assessed.

resultsIOI was observed in 17 eyes from 14 patients, including anterior uveitis (AU, n = 7), intermediate uveitis (IU, n = 5), and panuveitis with or without retinal vasculitis (RV, n = 5). Two eyes were asymptomatic. The median duration for IOI onset was 26 days, with 11 of 17 eyes (82.4%) developing IOI before the third brolucizumab injection. Firth-penalized multivariate Cox regression analysis depicted that the total number of anti-VEGF injections within one year prior to brolucizumab initiation (HR = 1.4, p = 0.009) and retinal angiomatous proliferation (RAP) (HR = 10.9, p = 0.009), may be associated with IOI development. In contrast, baseline macular neovascularization (MNV) size and the presence of retinal pigment epithelial and outer retinal atrophy were not associated with IOI occurrence.

conclusionVigilant examination after the initial brolucizumab injections is critical. Patients with identified risk factors may need meticulous monitor following brolucizumab injections.

Indexed as

Antibodies, Monoclonal, HumanizedUveitisVisual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsBiomarkersFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleRetrospective StudiesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBiomarkersbrolucizumabVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorBrolucizumabIntraocular inflammationNeovascular age-related macular degeneration

Identifiers

PMID41372725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.